There’s plenty of ongoing clinical trials, I think there’s almost over 50 clinical development programs currently ongoing globally for amyotrophic lateral sclerosis (ALS). That means that we have to get through these pretty quickly. One of the highlights from the presentation that I’ll be giving is talking about being innovative in clinical trials. One is the HEALEY ALS Platform Trial: where we try to test multiple therapies in an infrastructure that’s already set up so that we can quickly evaluate a therapy and see if it can be graduated to a confirmatory Phase III...
There’s plenty of ongoing clinical trials, I think there’s almost over 50 clinical development programs currently ongoing globally for amyotrophic lateral sclerosis (ALS). That means that we have to get through these pretty quickly. One of the highlights from the presentation that I’ll be giving is talking about being innovative in clinical trials. One is the HEALEY ALS Platform Trial: where we try to test multiple therapies in an infrastructure that’s already set up so that we can quickly evaluate a therapy and see if it can be graduated to a confirmatory Phase III. Since 2020, five therapies have been evaluated. Within those, two of them have shown some preliminary signals that warrant further investigation. There are two ongoing, two additional (the sixth and seventh investigational product), which are actually ongoing in the HEALEY Platform Trial. We’ll await results later this year.
